To evaluate the impact of herpes zoster vaccine on the incidence of herpes zoster and survival in lung cancer patients, and to explore its preventive effect and safety.
Study Type
OBSERVATIONAL
Enrollment
500
Receive the herpes zoster vaccine; Do not receive the herpes zoster vaccine
The incidence of herpes zoster at 12 months
During the 12-month follow-up period, the incidence of herpes zoster in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.
Time frame: 12 months
Incidence of herpes zoster
The proportion of lung cancer patients who developed herpes zoster during the study period.
Time frame: 24 months
Survival rate
The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years).
Time frame: 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.